[go: up one dir, main page]

AU2001269326A1 - Screening method - Google Patents

Screening method

Info

Publication number
AU2001269326A1
AU2001269326A1 AU2001269326A AU6932601A AU2001269326A1 AU 2001269326 A1 AU2001269326 A1 AU 2001269326A1 AU 2001269326 A AU2001269326 A AU 2001269326A AU 6932601 A AU6932601 A AU 6932601A AU 2001269326 A1 AU2001269326 A1 AU 2001269326A1
Authority
AU
Australia
Prior art keywords
cell
apoptopic
exposing
identifying
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269326A
Inventor
Tom Cotter
Ian Hayes
Finbarr Murphy
Liam Seery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EiRx Therapeutics Ltd
Original Assignee
EiRx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0016692.6A external-priority patent/GB0016692D0/en
Application filed by EiRx Therapeutics Ltd filed Critical EiRx Therapeutics Ltd
Publication of AU2001269326A1 publication Critical patent/AU2001269326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a method for identifying a gene product which modulates the transition of a cell between a non-apoptopic state and an apoptopic state, comprising the steps of: (a) exposing the cell to an inhibitor of GM-CSF mediated inhibition of apoptosis; and (b) exposing the cell to one or more agents which increase tyrosine phosphorylation; and (c) placing the cell in conditions which permit it to undergo spontaneous apoptosis; and (d) monitoring the level(s) of expression of the one or more gene products in the cell; and (e) identifying gene product(s) whose expression has been increased, decreased or modified as a result of performing steps (a) to (d).
AU2001269326A 2000-07-07 2001-07-09 Screening method Abandoned AU2001269326A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0016692.6 2000-07-07
GBGB0016692.6A GB0016692D0 (en) 2000-07-07 2000-07-07 Method
US25445900P 2000-12-08 2000-12-08
US60/254,459 2000-12-08
PCT/GB2001/003101 WO2002004657A2 (en) 2000-07-07 2001-07-09 Screening method

Publications (1)

Publication Number Publication Date
AU2001269326A1 true AU2001269326A1 (en) 2002-01-21

Family

ID=26244614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269326A Abandoned AU2001269326A1 (en) 2000-07-07 2001-07-09 Screening method

Country Status (5)

Country Link
EP (1) EP1299558B1 (en)
AT (1) ATE325889T1 (en)
AU (1) AU2001269326A1 (en)
DE (1) DE60119524T2 (en)
WO (1) WO2002004657A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352459A1 (en) * 2001-12-20 2003-07-09 Eirx Therapeutics Limited Early stage redox-related apoptosis modulator-2 (esram-2)
AU2004205785A1 (en) * 2003-01-23 2004-08-05 Eirx Therapeutics Limited Kinases and GPCRs involved in apoptosis
GB0305267D0 (en) * 2003-03-07 2003-04-09 Eirx Therapeutics Ltd Proteins involved in apoptosis
CA2612224A1 (en) * 2005-06-20 2007-01-04 Exelixis, Inc. Galk1s as modifiers of the pten/akt pathway and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1215433A (en) * 1996-12-02 1999-04-28 味之素株式会社 Gliotoxin derivatives and anticancer drugs made from it
AU765741B2 (en) * 1997-12-19 2003-09-25 Warner-Lambert Company Sag: sensitive to apoptosis gene

Also Published As

Publication number Publication date
EP1299558B1 (en) 2006-05-10
ATE325889T1 (en) 2006-06-15
WO2002004657A3 (en) 2003-01-16
WO2002004657A2 (en) 2002-01-17
EP1299558A2 (en) 2003-04-09
DE60119524D1 (en) 2006-06-14
DE60119524T2 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
WO1997040065A3 (en) Substrates and inhibitors of proteolytic enzymes
DE69918089D1 (en) BTK INHIBITORS AND METHOD FOR IDENTIFICATION AND USE
WO2003095636A3 (en) Activation induced deaminase (aid)
WO2001038532A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
NO990338L (en) cell adhesion inhibitor
WO2003073822A3 (en) Methods of diagnosing liver fibrosis
ATE290208T1 (en) DEVICE AND METHOD FOR PERFORMING ELECTRICAL MEASUREMENTS ON OBJECTS
DE602004023945D1 (en) PROCESS FOR REDUCING ACRYLAMIDE IN LIFE
EA200001129A2 (en) METHOD OF OBTAINING 4-CARBOXYAMINO-2-SUBSTITUTE-1,2,3,4-TETRAHYDROCHINOLINE
ATE271037T1 (en) SUBSTITUTED CARBAZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SPLA2 INHIBITORS
DE69818278D1 (en) STEROID SULFATAS INHIBITORS, METHOD FOR THEIR PRODUCTION AND USE
ATE263236T1 (en) STEM CELL PROLIFERATION INHIBITOR AND USE THEREOF
EP1509250A4 (en) Methods compositions and articles of manufacture for modulating bone growth
AU2003274187A1 (en) Method for monitoring and analyzing a paper production process
AU2001269326A1 (en) Screening method
WO2000040757A3 (en) Method of identifying nucleic acids
WO2004042352A3 (en) Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates
ATE457371T1 (en) METHOD AND DEVICE FOR MAGNETRON SPUTTERING
DE69710744D1 (en) METHOD FOR BIOTRANSFORMING COLCHICINOID COMPOUNDS IN THE CORRESPONDING 3-GLYCOSYL DERIVATIVES
AU2001260314A1 (en) Method for selecting enzyme inhibitors
PL330227A1 (en) Method of obtaining phenylheterocyclic compounds suitable as cox-2 inhibitors
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation
AU2003219630A1 (en) A method and a device for measuring stress forces in refiners
WO2000026634A3 (en) Compositions and methods for screening agents that inhibit mapk mediated anti-apoptotic signals